A recent phase 3 APTneo Michelangelo trial added Tecentriq to neoadjuvant Herceptin plus Perjeta and chemotherapy which did not lead to a statistically significant improvement in pathologic complete response in patients with HER2-positive operable breast cancer.
One atezolizumab-based combination did not improve pCR, but another one did, when used as neoadjuvant treatment in HER2-positive breast cancer. One atezolizumab-based combination did not improve pCR, but another one did, when used as neoadjuvant treatment in HER2-positive breast cancer.
The addition of atezolizumab to neoadjuvant trastuzumab plus pertuzumab (HP) and chemotherapy led to a numerical, but not statistically significant, increase in pathologic complete response vs HP/chemotherapy alone in patients with HER2-positive operable breast cancer.
The Michelangelo trial revealed that adding atezolizumab to nab-paclitaxel and carboplatin did not improve 5-year event-free survival in patients with triple-negative breast cancer.